FDAWarning letter
FDA warning letter to SwissChems over semaglutide and retatrutide
The FDA warned SwissChems that its semaglutide and retatrutide products — sold as research chemicals but promoted for human weight and metabolic use — are unapproved new drugs and misbranded under the FD&C Act. It is one of a series of letters the agency has issued to vendors offering GLP-1 and research peptides directly to the public.
Source
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/swisschems-695663-12102024The issuing body’s own page is authoritative. PepIndex records what it says and when we recorded it; where the two disagree, the source governs.